Peritoneal Cancer

Despite palliative chemotherapy (cyclophosphamide and vincristine), the patient experienced rapid tumor recurrence and progressive clinical deterioration, culminating in death three weeks post-intervention. In resource-limited settings, where advanced molecular diagnostics are scarce, maintaining a high index of clinical suspicion and ensuring multidisciplinary management are paramount. Early histopathological confirmation is critical to addressing the rapid progression and therapeutic resistance characteristic of this malignancy.

P3, N=520, Active, not recruiting, AbbVie | Trial primary completion date: May 2032 --> Apr 2027

P2, N=80, Recruiting, MacroGenics | N=60 --> 80 | Trial completion date: Aug 2027 --> Dec 2027 | Trial primary completion date: Feb 2027 --> Jul 2027

Spectral CT iodine quantification demonstrates potential as a complementary tool for estimating peritoneal metastasis burden and predicting surgical resectability. The NIC threshold of 0.55 shows promise for stratifying patients, though external validation is needed before integration into preoperative staging protocols.

P1/2, N=36, Recruiting, Beijing Biotech

However, no significant associations were found between these SNPs and salpingitis susceptibility. Given the genetic heterogeneity among Han Chinese populations across different regions, these findings from a single center in Sichuan should be validated in multi-regional cohorts to generalize their applicability.

Neoadjuvant treatment with T-DXd plus 5-FU/FA was found to be well tolerated and showed preliminary signs of activity during the safety run-in period of the NeoART study.

P2, N=21, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed

Survival was negatively correlated with PD-L1, TNF-α, IL-6, and IL-10 in colorectal cancer; 4-1BB, TGF-β1, IL-8, and IL-10 in gastric cancer; and TGF-β1, IL-6, and IL-10 in pancreatic cancer. These exploratory findings indicate that the immunosuppressive milieu in malignant ascites in gastrointestinal cancers may be mediated by cancer subtype-specific pathways, warranting further mechanistic and translational investigation.

Single-cell profiling reveals dedifferentiation from differentiated states in primary AC into intestinal stem cell and fetal progenitor states in AC-PC, with upregulation of oncogenic signaling pathways. We identify KRASMULTI-ON inhibitor RMC-7977 and the Wnt-targeting tyrosine kinase inhibitor WNTinib as clinically actionable strategies to target AC-PC more effectively.

P2, N=110, Recruiting, AbbVie | Trial primary completion date: Mar 2028 --> Jul 2026

P3, N=520, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2027 --> May 2032